Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis

Triple negative breast cancer(TNBC) represents a significant therapeutic challenge due to its highly aggressive nature and lack of effective treatment options. Liposomal irinotecan(nal-IRI, ONIVYDE) was approved in 2015 (by the Food and Drug Administration, European Medicines Agency, and Therapeutic Goods Administration) and is a topoisomerase inhibitorindicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinomaof the pancreas after disease progression following gemcitabine-based therapy. This study investigates the potential therapeutic benefit of nal-IRI for the treatment of advanced TNBC in a clinically relevant mouse model of spontaneous metastasis (LM2–4). Female SCID mice were orthotopically inoculated with TNBC LM2–4-luc cells in the lower mammary fat pad. Following primary tumor resection, bioluminescence imaging(BLI) was used to monitor both metastasis formation and spread as well as response to treatment with nal-IRI. Weekly treatm...